🔴 Cue Biopharma is trading 10% down with no clear company-specific catalyst

Cue Biopharma is trading 10.25% down at $24.82, with no clear company-specific catalyst identified for the October 12 decline.

• Cue Biopharma’s investor-relations page highlights earlier positive CUE-221 Phase 2 results; October 11 coverage discussed those results, not a new event explaining Monday’s drop.
• Market context was mixed, with no major index down more than 0.5%, and does not clearly explain the move.
• Shares had risen 23.87% on October 9, though timing alone does not establish a cause for the decline.